Regenerative Pharmaceuticals executives said the company expects to launch critical clinical trials of REGN 20423 in late 2027 or early 2028.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.